Background: Gastric cancer (GC) development is a multistep process, during which numerous alterations accumulate in nuclear and mitochondrial DNA. A deficiency of repair machinery brings about an accumulation of errors introduced within simple repetitive microsatellite sequences during replication of DNA. Aberrant methylation is related to microsatellite instability (MSI) by the silencing of the hMLH1 gene. The aim of this study is to investigate a possible relationship between the RUNX3 promoter methylation, nuclear microsatellite instability (nMSI) and mitochondrial microsatellite instability (mtMSI), in order to clarify its biological role in GC.
introduction
Gastric cancer (GC) is the second most common malignant neoplasm throughout the world and the second most frequent cause of cancer death [1] . GC development is a multistep process, during which numerous genetic and epigenetic alterations accumulate. In various human malignancies, alterations do not only involve nuclear but also mitochondrial DNA. Microsatellite instability (MSI) phenotype is characterized by the presence of errors during DNA replication, such as small deletions and or insertions, within simple repetitive microsatellite sequences [2] . In order for the cell to accurately copy its genome during cellular proliferation, the DNA mismatch repair (MMR) complex is essential. Deficiencies of this system result in a subsequent failure to repair errors introduced during replication of DNA [3] . The mitochondrial genome (mtDNA) is made up of 16 569 bp and encodes 13 polypeptides, 22 transfer RNAs and two ribosomal RNAs, all of which are essential for electron transport and ATP generation. All the mitochondrial genes are organized continuously, there being only two noncoding regions. The 1.1-kb displacement (D)-loop contains the main regulatory sequences for transcription and replication initiation [4] . A mononucleotide repetition of poly-C, (D310), has been identified among the nucleotides 16184 and 16193 and can be considered as a marker for the study of mitochondrial instability in GC [5] . For the analysis of the nuclear microsatellite instability (nMSI), we followed the guidelines provided by the National Cancer Institute (NCI) in 1997 recommending a panel of five microsatellite markers [6] . Nuclear MSI can be classified as high-level microsatellite instability (MSI-H), low-level microsatellite instability (MSI-L) or stable microsatellite instability (MSS) . No correlation between nuclear and mitochondrial MSI was found in colorectal, breast and renal cancers [7] . Results involving GC, however, prove to be fairly controversial [8, 9, 32] . A further molecular defect described in gastric cancer is aberrant methylation of the cytosine within the CpG islands, a phenomenon associated with loss of gene expression by transcription repression [10] . Some GCs show a high degree of concordant methylation of CpG islands; these types of tumors are classified as high CpG island methylator phenotypes (CIMP) [9] . CIMP is closely related to MSI phenotypes; in fact in most sporadic GCs, nMSI is due to the silencing of hMLH1, which is a MMR gene [11] [12] [13] [14] . In addition to aberrant methylation of the 5# CpG islands of hMLH1, several other tumor-related genes such as E-cadherin, APC, RASSF1A, DCC and PTEN have also been described in GC [15] [16] [17] [18] [19] . Recently, RUNX3 has been shown to be among the gene promoters that are most specifically methylated in CIMP-positive gastric cancer [20] . RUNX3 is a tumor suppressor gene located on chromosome 1p36, a region that is thought to carry a tumor suppressor gene implicated in various types of cancers, especially those of the gastrointestinal tract [21] . Together with RUNX1 and RUNX2, it belongs to the runt related transcription factors (RUNXs), which respond to the growth, differentiation and apoptosis signals induced by the TGF-b pathway [22] [23] [24] . RUNX3 loss of expression by promoter hypermethylation is involved in roughly half of the cases of GC and is mostly cancer specific, although recent studies have demonstrated that promoter methylation occurs also in non-neoplastic cells during aging [25, 26] . No study to date has examined relationship between RUNX3 promoter methylation, nMSI and mitochondrial microsatellite instability (mtMSI) in GC. The purpose of this study was to investigate a possible relationship between these events in order to clarify the biological role in GC and to associate the resulting data with available clinicopathological variables.
patients and methods

clinicopathological variables
A prospective study was conducted on a consecutive series of 100 patients affected by GC who had undergone potentially curative surgical resection at the Department of Oncology of Palermo University between 1999 and 2007. The following clinicopathological variables were taken into account: sex, age, tumor site, tumor size, tumor histotype, histological grade, tumor-node-metastasis (TNM) staging, invasion, and lymph node status ( Table 1) . None of the patients had undergone radio or chemotherapy before surgery; curative resection included gastrectomy and wide dissection of the regional lymph nodes. The excised GC and the lymph nodes were examined and staged according to the most recent TNM classification. Histological sections of the 100 operated pieces were examined separately by two pathologists (Rosa Maria Tomasino and Vincenza Morello). Lauren's criteria were used in order to classify the tumors into intestinal or diffuse types. Differentiation was evaluated and classified as G1, G2 or G3.
sampling
After obtaining informed consent, multiple samples (from 3 to 10) were taken from the various representative areas of the primary GC within 30 min of surgical resection. Each tissue specimen was carefully analyzed to make sure that, as far as possible, all non-neoplastic material had been removed and also to eliminate nonvital areas. Furthermore, a sample of apparently healthy mucosa as far away as possible from the tumor was taken from each patient to be used as a standard control for the subsequent biomolecular investigation. After sampling, all tissues were immediately frozen and stored at 280°C. 
nMSI and mtMSI
For the analysis of the nMSI, we followed the NCI guidelines, which in 1997 recommended a panel of five microsatellite markers for detection of MSI, consisting of two mononucleotide-repeats (BAT-25 and BAT-26) and three dinucleotide repeats (D2S123, D5S345 and D17S250). This panel of markers is referred to as the Bethesda panel [6] and provides a uniform set of markers and criteria for tumor classification that has helped standardize MSI analysis. PCR was performed on a total volume of 15 ll with the use of 30 ng of genomic DNA, 1.5 ll of 10· 25 mM MgCl 2 buffer, 0.6 ll of 25 mM MgCl 2 , 0.6 ll of 10 mM deoxyribonucleotide triphosphate (dNTP), 0.12 ll of 5 U/ll AmpliTaq Gold (Applied Biosystems, Foster City, CA), 1 ll of 5 lM FAM or HEX-labeled forward primer and 1 ll of 5 lM unlabeled reverse primer. Mitochondrial instability was assessed by analyzing a portion of the D-loop, the mononucleotide tract of poly-C (D310) made up of 12-18 C interrupted by a T at bp10, following the same conditions for the PCR of nMSI but with the use of specific primers for the D310 region: FAMlabeled forward primer 5#-ACA GCC ACT TTC CAC ACA G-3# and reverse primer 5#-TGG TTA GGC TGG TGT TAG GG-3#. Most of the alterations generally occur in the upstream portion of T.
The reaction was assessed on the GeneAmp 9700 (Applied Biosystems). Amplification was started with 12 min at 95°C, followed by 10 cycles composed of 15 s at 94°C, 15 s at 55°C and 30 s at 72°C. This was followed by 25 cycles composed of 15 s at 89°C, 15 s at 55°C and 30 s at 72°C. Approximately 1-2 ng of each PCR product were mixed with a 1:40 dilution of formamide-Gene scan 400 HD standard size (Applied Biosystems), denatured at 95°C for 2 min and visualized on an ABI PRISM 3100 Avant Genetic Analyzer (Applied Biosystems) Applied Biosystems. DNA alterations were detected using a GeneMapper software version 3.5. Samples were considered positive for MSI when alternate-sized bands were present in the tumor DNA but absent in mucosa DNA. Tumors showing nuclear instability were classified as MSI-H when two or more markers showed allelic shifts, as MSI-L if only one marker shows an allelic shift and as MSS when no marker showed an allelic shift. Tumors showing mtMSI were confirmed by direct sequencing on ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). The results were analyzed with the use of the software Sequencing Analysis 5.1 in order to detect the possible coexistence of several different variants (mutated or wild type) along the mononucleot tract (heteroplasmy).
Methylation Specific PCR
DNA methylation of RUNX3 was determined by methylation-specific PCR (MSP). MSP distinguishes unmethylated (UM) from M alleles of a given gene based on DNA sequence alterations after bisulfite treatment of DNA, which converts UM but not M, cytosines to uracils. Subsequent PCR using primers specific to sequences corresponding to either M or UM DNA sequences is then performed. Bisulfite modification of genomic DNA was carried out essentially as described previously [27] . Briefly, 2 lg of genomic DNA was denatured with 5.5 ll of 2 M NaOH, freshly prepared for 10 min at 37°C. We then added and mixed 30 ll of freshly prepared 10 mM hydroquinone and 520 ll of freshly prepared 3 M sodium bisulfite at pH 5. The samples were then incubated in mineral oil for 16 h at 50°C. The modified DNA was purified with a Wizard DNA clean-up system (Promega, Madison, WI). After purification, the samples were treated with NaOH (0.3 M) for 5 min at 37°C. The DNA was then ethanol precipitated and resuspended in 20 ll of water for MSP analysis. The bisulfite-induced changes affecting UM and M alleles were detected by PCR. Primer sequences for the UM reaction were 5#-TTATGAGGGGTGGTTGT ATGTGGG-3#(forward) and 5#-AAAACAACCAACACAAACACCTCC-3# (reverse), and primer sequences for the M reaction were 5#-TTACGAGGGGCGGTCGTACGCGGG-3# (forward) and 5#-AAAACGACCGACGCGAACGCCTCC-3# (reverse). The primers, which amplify the proximal regional (-218 and -69) of the initial transcription site, were designed by taking into consideration the whole sequence of the gene codifying RUNX3, containing also the P2 promoter sequence (GeneBank Access number AL023096), where there is a long CpG (4.2 kb) island. The PCR was performed in a total volume of 50 ll, using 5 ll of 10· 25 mM MgCl 2 buffer, 1.5 ll of dNTP 10 mM, 2.5 ll of forward primer (UM and M) 10 lM, 2.5 ll of reverse primer (UM and M) 10 lM, 0.3 ll of 5U/ll AmpliTaq Gold (Applied Biosystems) and about 30 ng of bisulfite-modified DNA. The amplification was performed on GeneAmp 9700 thermocycler (Applied Biosystems) under the following conditions: predenaturation at 95°C for 10 min, 35 amplification cycles (denature at 94°C for 30 s, annealing at 66°C for 40 s and extension at 72°C for 1 min) and final extension at 72°C for 7 min. The product indicative of an UM RUNX3 allele and of a M RUNX3 allele were analyzed on 2% agarose gels and photographed. CpG Universal M DNA (Chemicon International, CA) was used as the positive control for M alleles, CpG Universal UM DNA (Chemicon International), as a negative control for M genes, 100 bp DNA ladder as size marker. MSP assay for each sample was repeated at least twice.
bisulfite sequencing
In order to verify MSP, bisulfite sequencing was performed by automated sequencing using the Big Dye Terminator v3.1 Cycle Sequencing Kit and the model ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
statistical analysis
Associations between biomolecular and clinicopathological variables were evaluated by the chi-square test with Yates correction, where appropriate. A P value <0.05 was considered statistically significant.
results methylation status of RUNX3 in gastric cancers
To determine aberrant CpG island methylation of RUNX3, we analyzed the promoter region spanning the transcription start site of 40 gastric cancers using MSP. In total, 55% (22/40) of GC demonstrated complete methylation of the RUNX3 promoter. M GC always displayed evidence of an accompanying UM PCR product (Figure 1 ). These UM RUNX3 alleles most likely reflect either the unavoidable presence of normal cells in the cancer specimen or heterogeneity of the methylation event within the tumor cell population itself. Methylation observed is relatively cancer specific since only two of 40 cases showed evidence for aberrant RUNX3 methylation in the normal mucosa of older patients (data not shown). Bisulfite direct sequencing was performed on all of these normal and tumor samples to confirm the accuracy of the MSP results (Figure 2 ).
nuclear MSI
None of the 100 patients analyzed had a family history of gastric cancer. Overall, 82% of GC was classified as MSS, 5% Figure 3C ). It is interesting to note that instability in D2S123 was detected in all the five tumors with MSI-L ( Figure 3D ).
mitochondrial MSI
mtMSI was detected in 11% (11/100) of GC. Seven (64%) of the changes were deletions and four (36%) were insertions. Most of the deletions and insertions involved 1-2 bp. The largest alteration was a 4-bp deletion seen in two cases. In one case there was a 3 bp insertion. An example of the DNA fragment and sequencing analysis is shown in Figure 4 . After analysis of chromatograms obtained by DNA sequencing, seven of 11 (64%) of alterations were evaluated to be heteroplasmic and four of 11 (36%) homoplasmic.
relationship between mtMSI, nMSI, RUNX3 methylation status and clinicopathological variables
The clinicopathological variables of GC patients are summarized in Table 1 . No significant association was found between biological variables analyzed and sex, age, tumor site, tumor size, tumor histotype histological grade, invasion or lymph node status (data not shown). The only significant association was detected between mtMSI and TNM staging (P < 0.025) ( Table 2) . Statistical analysis highlighted an interesting association between MSI-H status, mtMSI and RUNX3 methylation (Tables 2 and 3 ).
discussion
Tumor-related genes tend to be preferentially inactivated by specific genetic or epigenetic mechanisms. Accumulating evidence suggests that epigenetic silencing of tumor suppressor genes due to aberrant hypermethylation of gene promoter regions play an important role in gastric cancer pathophysiology [28] . Concordant methylation of multiple genes (termed CIMP) has been reported in carcinomas from diverse sites. The methylation affects several critical molecular pathways leading to cell immortalization and transformation, including alterations in cell cycle regulation, metabolic detoxification enzymes, cellular adherence and the DNA damage response pathways [29] . Recently, a causal relationship has been identified between aberrant methylation of the promoter of RUNX3 and the incidence of gastric cancer in humans [20] . The results obtained from this study demonstrated that 55% (22/40) of human GCs presented hypermethylation of the promoter region of the gene and only two of 40 cases also showed methylation of the RUNX3 promoter in the nonmalignant gastric tissue. Our results indicate that RUNX3 promoter methylation is a cancerspecific event. A possible explanation for detecting methylation in normal gastric tissues is that the methylation of RUNX3 has been attributed to the aging process, and this is similar to previous findings in which methylation was observed in people >70 years of age [26] . The data reported in literature show differences in methylation frequency of the gene RUNX3. In a previous study, Waki et al. [26] reported that RUNX3 methylation was observed in 45% of GCs; other investigators reported that RUNX3 methylation was observed in 71% of GCs [30] . These data can be explained by the fact that different regions were examined within the RUNX3 CpG island. Homma et al. [31] studied the whole RUNX3 CpG island and showed that the 5# outskirt region is not informative. In contrast, methylation spanning the transcription start site within the RUNX3 promoter CpG island is predominantly cancer specific and is critical for gene silencing. In our study of sporadic GCs, the association between RUNX3 promoter methylation, nMSI and mtMSI showed significant associations, suggesting that these cancers have acquired a ÔmethylatorÕ phenotype. The mechanism of cancer development proposed for sporadic MSI-H GCs is the aberrant promoter methylation of hMLH1 with the consequent functional loss of MMR genes [14] . All the mtDNA repair machinery is encoded by nDNA, and the corresponding gene Annals of Oncology symposium article products are subsequently transported into the mitochondria. This indicates that there might be a common cause for the onset of mtMSI and nMSI. In the present study, mitochondrial and nuclear instability were examined in 100 GCs. The prevalence of mtMSI and nMSI-H in gastric cancer varies among different studies, and the relationship between the occurrence of these alterations remains controversial [8, 9, 32] . We found that 11% of the gastric cancer patients had alterations in the D310 poly-C tract in the D-loop; 13% of the cases showed MSI-H, 5% MSI-L and 82% MSS. These data are in concordance with previous studies [8, 9] . The mtMSI was significantly associated with nMSI, in fact, nine of 11 cases positive for mtMSI showed MSI-H. In several studies, the MSI-H, mtMSI and RUNX3 promoter methylation in GC have been associated with several clinicopathological variables, although several reports come to different conclusions [30] [31] [32] [33] [34] . In the present study, no association was found with any of the clinicopathologic variables; mitochondrial instability only proved to be associated with the TNM staging. Up to now, no study had ever examined the relationship between RUNX3 promoter methylation, nuclear and mitochondrial MSI in GC. Our data highlight a significant association between these events in gastric cancer, suggesting that RUNX3 is an important target of methylation in the evolution of mtMSI and nMSI-H GC.
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